Company announces positive topline results for Nefecon (targeted-release oral budesonide formulation) for treatment of IgA nephropathy

RCT (n=199) met primary objective of demonstrating statistically significant reduction in urine protein creatinine ratio (UPCR or proteinuria), after 9 months of treatment with 16mg dose vs. placebo, with continued improvement at 12 months. Regulatory submissions planned in 2021

Source:

Biospace Inc.